Thomas Holst‐Hansen

432 total citations · 1 hit paper
11 papers, 286 citations indexed

About

Thomas Holst‐Hansen is a scholar working on Endocrinology, Diabetes and Metabolism, Pharmacology and Molecular Biology. According to data from OpenAlex, Thomas Holst‐Hansen has authored 11 papers receiving a total of 286 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Endocrinology, Diabetes and Metabolism, 6 papers in Pharmacology and 5 papers in Molecular Biology. Recurrent topics in Thomas Holst‐Hansen's work include Diabetes Treatment and Management (8 papers), Pharmacology and Obesity Treatment (6 papers) and Metabolism, Diabetes, and Cancer (5 papers). Thomas Holst‐Hansen is often cited by papers focused on Diabetes Treatment and Management (8 papers), Pharmacology and Obesity Treatment (6 papers) and Metabolism, Diabetes, and Cancer (5 papers). Thomas Holst‐Hansen collaborates with scholars based in Denmark, United States and United Kingdom. Thomas Holst‐Hansen's co-authors include Peter Nørkjær Laursen, Domenica Rubino, Vanita R. Aroda, Filip K. Knop, Julio Rosenstock, W. Timothy Garvey, Michael Junkin, Minjun Son, Sara Saheb Kashaf and Savaş Tay and has published in prestigious journals such as The Lancet, Diabetes and Science Advances.

In The Last Decade

Thomas Holst‐Hansen

11 papers receiving 282 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial

2023 231 citations Filip K. Knop, Vanita R. Aroda et al. The Lancet profile →

Peers

Thomas Holst‐Hansen

EDM

PHARM

MB

PHYSI

SURGE

Thalia Panagiotopoulou Greece

Julia Kenkre United Kingdom

Elio Ippolito Italy

Hermina Jakupović Finland

Christian Anholm Denmark

Renate E. van Genugten Netherlands

Liuxin Wang China

Surya Panicker Rajeev United Kingdom

Maja Baretić Croatia

Eiji Ueyama Japan

Thalia Panagiotopoulou Greece

Thomas Holst‐Hansen

270 ×1.3

EDM

105 ×0.7

PHARM

100 ×1.2

MB

73 ×0.9

PHYSI

92 ×2.3

SURGE

Citations per year, relative to Thomas Holst‐Hansen Thomas Holst‐Hansen (= 1×) peers Thalia Panagiotopoulou

Countries citing papers authored by Thomas Holst‐Hansen

Since Specialization

Citations

This map shows the geographic impact of Thomas Holst‐Hansen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Holst‐Hansen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Holst‐Hansen more than expected).

Fields of papers citing papers by Thomas Holst‐Hansen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Holst‐Hansen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Holst‐Hansen. The network helps show where Thomas Holst‐Hansen may publish in the future.

Co-authorship network of co-authors of Thomas Holst‐Hansen

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Holst‐Hansen. A scholar is included among the top collaborators of Thomas Holst‐Hansen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Holst‐Hansen. Thomas Holst‐Hansen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

1.

Knop, Filip K., George Kunos, Dror Dicker, et al.. (2025). Efficacy and safety of monlunabant in adults with obesity and metabolic syndrome: a double-blind, randomised, placebo-controlled, phase 2a trial. The Lancet Diabetes & Endocrinology. 13(11). 911–923. 1 indexed citations

2.

Holst‐Hansen, Thomas, et al.. (2024). The Correlation Between Body Mass Index and Health-Related Quality of Life: Data from Two Weight Loss Intervention Studies. Advances in Therapy. 41(11). 4228–4247. 1 indexed citations

3.

Holst‐Hansen, Thomas, et al.. (2024). The association between body mass index and health‐related quality of life in the 2017 and 2018 health survey of England data: A cross‐sectional observational analysis. Diabetes Obesity and Metabolism. 26(6). 2318–2328. 6 indexed citations

4.

Allen, Felicity, et al.. (2024). Treatment effect of semaglutide 2.4 mg on health‐related quality of life from STEP 1 SF‐6D derived from SF ‐36 with Australian weights. Diabetes Obesity and Metabolism. 26(4). 1171–1179. 2 indexed citations

5.

Bjørner, Jakob Bue, et al.. (2023). The improved health utility of once‐weekly subcutaneous semaglutide 2.4 mg compared with placebo in the STEP 1‐4 obesity trials. Diabetes Obesity and Metabolism. 25(8). 2142–2150. 4 indexed citations

6.

Holst‐Hansen, Thomas, et al.. (2023). Effect of semaglutide 2.4 mg once weekly on 10‐year type 2 diabetes risk in adults with overweight or obesity. Obesity. 31(9). 2249–2259. 10 indexed citations

7.

Knop, Filip K., Vanita R. Aroda, Thomas Holst‐Hansen, et al.. (2023). Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. 402(10403). 705–719. 231 indexed citations breakdown →

8.

Batterham, Rachel L., et al.. (2023). IMPACT OF ONCE-WEEKLY SUBCUTANEOUS SEMAGLUTIDE 2.4 MG ON METABOLIC SYNDROME IN THE 2-YEAR, RANDOMIZED CONTROLLED STEP 5 TRIAL. Canadian Journal of Cardiology. 39(10). S161–S162. 1 indexed citations

9.

Son, Minjun, Thomas Holst‐Hansen, Michael Junkin, et al.. (2022). Spatiotemporal NF-κB dynamics encodes the position, amplitude, and duration of local immune inputs. Science Advances. 8(35). eabn6240–eabn6240. 24 indexed citations

10.

Holst‐Hansen, Thomas, et al.. (2022). POSC350 Health Utility Values in the STEP 1–4 Trials of Semaglutide 2.4 MG in Obesity. Value in Health. 25(1). S240–S240. 1 indexed citations

11.

Holst‐Hansen, Thomas, et al.. (2022). 2-LB: Semaglutide 2.4 mg Reduces the 10-Year T2D Risk in People with Overweight/Obesity. Diabetes. 71(Supplement_1). 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact